NCBiotech News

North Carolina’s global gene therapy leadership was boosted today with the announcement that AveXis, Inc., is doubling its planned workforce and investing $60 million more in its new Durham County manufacturing facility.

Kriya Therapeutics will focus on building internal manufacturing infrastructure in Durham after securing $80.5 million Series A financing.

AskBio has acquired BrainVectis, a French company that is developing a potential gene therapy for Huntington’s disease, a fatal genetic disease of the brain.

Burlington-based LabCorp has introduced a suite of cell and gene therapy development services from Covance, its drug development business, to help biopharmaceutical companies develop cell and gene therapies for cancer and other diseases.

There’s hope on the horizon for people struggling with the rare neurogenetic disorder Angelman syndrome, thanks to a newly formed partnership between AskBio and UNC.

AskBio has launched a unique outreach program, called AskFirst, to communicate information and support during clinical trials to patients and their families.

bluebird bio, a gene therapy company with operations in Durham, has launched for the first time its treatment for a severe inherited blood disorder, in Germany.

The FDA has accepted the company’s Investigational New Drug (IND) application and also granted the therapy Orphan Drug Designation, a status that gives companies tax reductions and other incentives to develop treatments for rare diseases.

SQZ Biotechnologies' tolerizing antigen carriers may help expand patient eligibility for AskBio's gene therapies.

After more than two decades of game-changing accomplishments in the life science world, AskBio CEO Sheila Mikhail has been “discovered” as the Springboard Enterprises 2019 Northstar Honoree.

Pfizer, the international biopharmaceutical giant, is expanding its gene therapy program with the purchase of a Durham property that will become a clinical manufacturing facility.

Viralgen, a Spanish contract development and manufacturing organization half owned by AskBio of Research Triangle Park, has gained vital regulatory status in Europe for producing gene therapies using AskBio’s manufacturing process.

North Carolina is a global leader in gene therapy thanks to its renowned workforce development programs and the scientific output of its research universities.

Emboldened by a recent cash infusion of $225 million from investors, AskBio has acquired Scottish company Synpromics to help it develop therapeutics for a wider array of genetic disorders than the rare diseases it has targeted to date. 

RTP's AskBio has entered a strategic partnership with Boston's Selecta to boost gene therapy's potential for re-dosing if needed.